Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 20vPnC in Healthy Chinese Infants
NCT07754539Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 20 in pneumococcal disease, sponsored by Pfizer. Started Jul 2026; status: recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07754539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754539.